Onpode
Cover art for AstraZeneca, Pfizer, and Astellas won FDA approval for a combo therapy with 42% lower death risk in bladder cancer—challenging surgery as standard

AstraZeneca, Pfizer, and Astellas won FDA approval for a combo therapy with 42% lower death risk in bladder cancer—challenging surgery as standard

November 15, 2026 · 9 min

Eliza Ward & Brian Reed

Hey — glad you're here, actually, because I've been sitting with this FDA news for the last hour and I genuinely don't know where to start. Same. What landed for you first? The death number. Forty-two percent reduction in risk of death versus surgery alone — that's what the VOLGA trial showed, and that's what…

On November 13, 2026, the U.S. Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) combined with enfortumab vedotin-ejfv (Padcev, co-developed by Pfizer and Astellas Pharma) as a perioperative treatment for adults with muscle-invasive bladder cancer (MIBC) who are ineligible for, or have declined, cisplatin-based chemotherapy.

0:009:29
Get the next episode on Health →

Follow it free — new episodes land in your feed.

Or make your own — any topic, in minutes

More Onpode episodes on Health →

About this episode

On November 13, 2026, the U.S. Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) combined with enfortumab vedotin-ejfv (Padcev, co-developed by Pfizer and Astellas Pharma) as a perioperative treatment for adults with muscle-invasive bladder cancer (MIBC) who are ineligible for, or have declined, cisplatin-based chemotherapy.

Grounded in 8 sources
FDA approves Imfinzi + Padcev for cisplatin-ineligible muscle-invasive bladder cancer ↗ · fda.gov
Pembrolizumab and Enfortumab Vedotin-ejfv Approved for Bladder Cancer | Research | AACR ↗ · aacr.org
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer ↗ · astrazeneca-us.com
Perioperative Imfinzi plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer ↗ · astrazeneca.com
Pre-surgery drug combo cuts death risk in bladder cancer ↗ · bioengineer.org
FDA approves Perioperative Imfinzi Regimen for muscle-invasive bladder cancer ↗ · geo.tv
Bladder Cancer Patients Who Cannot Take Cisplatin Gain FDA-Approved Imfinzi and Padcev Option Before Bladder Removal ↗ · medicaldaily.com
PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer ↗ · prnewswire.com
Read transcript

Brian Reed: Hey — glad you're here, actually, because I've been sitting with this FDA news for the last hour and I genuinely don't know where to start.

Eliza Ward: Same. What landed for you first?

Brian Reed: The death number. Forty-two percent reduction in risk of death versus surgery alone — that's what the VOLGA trial showed, and that's what got durvalumab and enfortumab vedotin approved today.

Eliza Ward: Wait — and the FDA moved six weeks ahead of its target date on this. Priority review, early finish. That's not routine.

Brian Reed: No, it's not. And the patient population matters here — cisplatin-ineligible muscle-invasive bladder cancer. These are people who can't tolerate the standard neoadjuvant chemo. So the 42% figure lands differently when you understand there wasn't much else before this.

Eliza Ward: Three companies in this, right? AstraZeneca on the durvalumab side — that's Imfinzi — and then Pfizer and Astellas on enfortumab vedotin, Padcev.

Brian Reed: Three companies, one trial, one approval. And a 49% composite risk reduction on top of the mortality number. The question I want to work through is what that actually means for someone sitting across from an oncologist.

Eliza Ward: That's the right question — but let me flag one thing first. The 49% and the 42% are both real. The toxicity side of this is not fully in view yet.

Brian Reed: And the number that actually closes that toxicity gap for me — the one that makes the risk feel worth naming — is the pathological complete response rate. Not the death number.

Eliza Ward: That's the one that made me stop. Forty percent versus eight.

Brian Reed: Forty versus eight — in the VOLGA trial. What does that actually mean in plain terms?

Eliza Ward: Think of it like pre-treating a stain before you wash it. You attack the cancer before the surgeon ever cuts. The surgery then finds — wait, actually the point is what the surgeon doesn't find. Four in ten patients who went into radical cystectomy had no detectable cancer left. Zero. The neoadjuvant combination did that before the blade touched anything.

Brian Reed: And for cisplatin-ineligible patients — the people whose kidneys or age or other conditions ruled out standard neoadjuvant chemo — that number existed nowhere before this. That's the population that showed up to surgery without having pre-treated anything.

Eliza Ward: Right — and that's what separates this from hype. Eight percent complete response with surgery alone isn't a baseline, it's a floor that barely existed.

Brian Reed: So is the paradigm shift the survival number, or is it actually this — that we now have a pre-surgical option for a population that didn't really have one?

Eliza Ward: It's the second one. The 42% is the headline. The 40% complete response is the mechanism that explains why regulators moved — and why Project Orbis was used to trigger simultaneous international review. Though — I want to be clear — which countries outside the U.S. have actually approved it versus which are still in review is not known yet. That's a live gap.

Brian Reed: So the speed was globally coordinated, but the actual access picture is still unresolved.

Eliza Ward: Unresolved — and that access gap is actually the smaller problem right now. The real issue is the safety side of VOLGA, because the trial confirmed more severe side effects in the durvalumab plus enfortumab vedotin arm than in surgery alone. And then just... stops there.

Brian Reed: It doesn't give you a number.

Eliza Ward: No grade 3-plus rates. No breakdown by type. Just — more common. That's not a toxicity profile, that's a flag without a measurement.

Brian Reed: So here's the scenario that actually bothers me. It's Monday morning. An oncologist has a 74-year-old patient — kidney disease, cisplatin is off the table. The doctor can cite the 42% death reduction from VOLGA. That number is real. But if that patient asks, okay, how likely am I to have a serious adverse event — what does the oncologist say?

Eliza Ward: She can't answer it. Not from VOLGA.

Brian Reed: And the people saying this approval is clean because the survival signal is so strong — I think that's the take that doesn't hold. The survival data is sourced. The toxicity burden is, I mean, it's genuinely uncharacterized. Those aren't the same confidence level.

Eliza Ward: And there's a reason to think it gets worse outside the trial. There's an Australian real-world study of pembrolizumab in neoadjuvant MIBC — found more immune-related adverse events in routine practice than KEYNOTE-905 reported. These populations carry more comorbidities than trial enrollees. So VOLGA's safety profile, whatever it actually is, may not hold when this moves into general use.

Brian Reed: Wait — so the Australian pembrolizumab data is telling us the gap between trial conditions and real practice is already measurable for a drug in the same class. And we're approving a second regimen for that same population without quantifying the toxicity in the first place.

Eliza Ward: That's the confirmed gap. And — there's a second problem underneath it, which is the competitor question. Pembrolizumab plus enfortumab vedotin is already approved for cisplatin-ineligible MIBC, based on KEYNOTE-905. Zero head-to-head data between the two regimens. We'll get into why that makes this considerably messier.

Brian Reed: Messier how? Because my read is — two approved options sounds like progress, until you ask which one.

Eliza Ward: That's exactly the problem. Pembrolizumab — Keytruda, Merck — plus enfortumab vedotin, approved for cisplatin-ineligible MIBC based on KEYNOTE-905/EV-303. Now VOLGA gives you durvalumab plus enfortumab vedotin for the same population. Zero head-to-head data. These are not interchangeable.

Brian Reed: Structurally different too, right? The VOLGA regimen delivers enfortumab vedotin only before surgery. That's not the same design as the pembrolizumab combination.

Eliza Ward: Not the same drug in a different box, no. Different sequencing, different checkpoint inhibitor — AstraZeneca's durvalumab versus Merck's pembrolizumab. And oncologists have no clinical basis right now for preferring one.

Brian Reed: So picture a tumor board. Somebody pulls up both approvals. What's the actual decision framework? Because it's not efficacy comparison — that data doesn't exist.

Eliza Ward: It defaults to — I mean, it probably defaults to familiarity. Which trial did your institution enroll in? Which drug rep got there first? That's not medicine, that's noise.

Brian Reed: And there's a subgroup problem underneath that too, right? Because wait — who exactly was in VOLGA?

Eliza Ward: This is the part that actually stopped me. VOLGA enrolled cisplatin-ineligible patients — but also patients who declined cisplatin. Those are not the same people medically. And the sources don't break out outcomes by subgroup. So that 49% composite risk reduction? We don't know if it holds equally for both groups or if it's being carried by one of them.

Brian Reed: So the number we've been anchoring to this whole conversation might not apply uniformly to the population it was approved for. That's — that's the thing to watch. When the subgroup data surfaces, it either validates this or it reframes everything.

Eliza Ward: And that's where I actually land. The VOLGA data is real. Forty-two percent reduction in death risk — that's not a soft signal. But AstraZeneca has an approved regimen, Merck has an approved regimen, enfortumab vedotin is a component of both, and there is no trial comparing them. That's not optionality. That's just — two things existing.

Brian Reed: And the question I genuinely don't know the answer to is — who runs that head-to-head? Like, FDA can't force it. AstraZeneca has no incentive to fund a trial that might show their drug loses to Merck's. Merck has the same problem in reverse. So does it fall to academic oncology networks? The NCI? Because if nobody picks it up, oncologists are choosing between VOLGA and KEYNOTE-905/EV-303 on incomplete information — I mean, indefinitely. That's not a 2027 problem, that's a right-now problem that just doesn't have a name yet.

Eliza Ward: No identified trial. That's the sourced answer. Nothing in what we have.

Brian Reed: So we're sitting here with two approved regimens for cisplatin-ineligible MIBC, a shared component in enfortumab vedotin, survival data from VOLGA that holds up — and no mechanism on the horizon for generating the one number that would actually resolve the clinical question. That's genuinely where this ends.

Eliza Ward: It is. Watch for subgroup data, watch for whether any cooperative group picks this up. Until then — yeah. It's open.